Our investigation revealed elevated LSM2 expression in gliomas through exploration of the TCGA database, LSM2 expression is significantly higher in GBM compared to lower-grade gliomas (LGG), and its expression correlates with the presence of IDH1 mutations and the 1p/19q non-deletion status. The gene discussed is LSM2; the disease is central nervous system cancer.